In vitro activity of the novel des-F(6) quinolone BMS-284756 against genetically characterized clinical streptococcal isolates, including isolates with reduced quinolone susceptibility [2]

Journal of Antimicrobial Chemotherapy

Volumn 49, Issue 4, 2002, Pages 698-701

  Schmitz, F J ^a,b   Milatovic, D ^b   Boos, M ^a   Mayer, S ^a   Fluit, A C ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GARENOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; TETRACYCLINE;

ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; IN VITRO STUDY; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STREPTOCOCCUS; STREPTOCOCCUS MILLERI; STREPTOCOCCUS MITIS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; STREPTOCOCCUS SALIVARIUS; STREPTOCOCCUS SANGUINIS;

EID: 0036235892     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/49.4.698     Document Type: Letter

References (6)

1. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756
2. In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8796 clinical bacterial isolates
3. Quinolone-resistance mechanisms and in-vitro susceptibility patterns among European isolates of Streptococcus mitis, Streptococcus sanguis, and Streptococcus pneumoniae
4. Comparative activities of six different fluoroquinolones against 9, 682 clinical bacterial isolates from 20 European university hospitals participating in the European SENTRY surveillance program
5. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically-Fifth Edition: Approved Standard M7-A5
6. In-vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus